Literature DB >> 8335853

Chronic hyperplastic sinusitis: association of tissue eosinophilia with mRNA expression of granulocyte-macrophage colony-stimulating factor and interleukin-3.

D L Hamilos1, D Y Leung, R Wood, A Meyers, J K Stephens, J Barkans, Q Meng, L Cunningham, D K Bean, A B Kay.   

Abstract

BACKGROUND: We investigated the association among tissue eosinophilia, cellular infiltration, and cytokine mRNA expression in chronic hyperplastic sinusitis (CHS).
METHODS: Percutaneous biopsies of the maxillary sinuses and nasal polyps were performed in 12 adult patients (six men and six women) of whom seven were nonallergic and 11 were asthmatic. Tissues were compared with biopsy specimens from the inferior and middle turbinates of normal control subjects.
RESULTS: Histologically, an eosinophil-predominant inflammatory infiltrate was seen in 10 of 12 patients, whereas a mild to moderate neutrophilic infiltrate was seen in 4 of 12 patients. As determined by immunocytochemistry, diseased tissues and normal control tissues differed significantly in terms of the number of activated (EG2+) eosinophils (p = 0.005) but not in terms of CD3+ or CD4+ T lymphocytes, elastase-positive neutrophils or CD68+ macrophages. The number of eosinophils did not correlate with that of any other cell type. By in situ hybridization, CHS tissues showed significantly higher numbers of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-3 mRNA-positive cells than normal control tissues (p = 0.002 and 0.0005, respectively) per high-powered field. There was a significant correlation between the number of infiltrating EG2+ eosinophils and cells that expressed mRNA for GM-CSF (r = 0.60, p = 0.041) or IL-3 (r = 0.69, p = 0.013). Furthermore, epithelial cells did not show detectable mRNA expression for GM-CSF or IL-3. No significant correlation was found between IL-5 mRNA expression and infiltrating EG2+ eosinophils in diseased tissues. However, the IL-5 density was significantly higher in the five patients with CHS who had positive allergy skin test results than in the seven patients with negative skin test results (p = 0.017) or in normal control subjects.
CONCLUSIONS: Our data support a role for GM-CSF and IL-3 in the eosinophilia characteristic of CHS and show that IL-5 mRNA expression is not a prominent feature of nonallergic inflammation. The cellular sources of GM-CSF and IL-3 in CHS remain to be definitely determined.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8335853     DOI: 10.1016/0091-6749(93)90035-e

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  20 in total

1.  Epigenetics of chronic rhinosinusitis and the role of the eosinophil.

Authors:  Kristin A Seiberling; Christopher A Church; Jason L Herring; Lawrence C Sowers
Journal:  Int Forum Allergy Rhinol       Date:  2011-08-26       Impact factor: 3.858

Review 2.  Is there a future for biologics in the management of chronic rhinosinusitis?

Authors:  Kent Lam; Robert C Kern; Amber Luong
Journal:  Int Forum Allergy Rhinol       Date:  2016-04-22       Impact factor: 3.858

Review 3.  Fungi in chronic hyperplastic eosinophilic sinusitis: reasonable doubt.

Authors:  Larry Borish; Lanny Rosenwasser; John W Steinke
Journal:  Clin Rev Allergy Immunol       Date:  2006-06       Impact factor: 8.667

4.  Overview of allergic mechanisms. Ebastine has more than an antihistamine effect.

Authors:  A Campbell; F B Michel; C Bremard-Oury; L Crampette; J Bousquet
Journal:  Drugs       Date:  1996       Impact factor: 9.546

5.  Neutrophils are a major source of the epithelial barrier disrupting cytokine oncostatin M in patients with mucosal airways disease.

Authors:  Kathryn L Pothoven; James E Norton; Lydia A Suh; Roderick G Carter; Kathleen E Harris; Assel Biyasheva; Kevin Welch; Stephanie Shintani-Smith; David B Conley; Mark C Liu; Atsushi Kato; Pedro C Avila; Qutayba Hamid; Leslie C Grammer; Anju T Peters; Robert C Kern; Bruce K Tan; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2016-12-18       Impact factor: 10.793

Review 6.  Rhinosinusitis: Establishing definitions for clinical research and patient care.

Authors:  Eli O Meltzer; Daniel L Hamilos; James A Hadley; Donald C Lanza; Bradley F Marple; Richard A Nicklas; Claus Bachert; James Baraniuk; Fuad M Baroody; Michael S Benninger; Itzhak Brook; Badrul A Chowdhury; Howard M Druce; Stephen Durham; Berrylin Ferguson; Jack M Gwaltney; Michael Kaliner; David W Kennedy; Valerie Lund; Robert Naclerio; Ruby Pawankar; Jay F Piccirillo; Patricia Rohane; Ronald Simon; Raymond G Slavin; Alkis Togias; Ellen R Wald; S James Zinreich
Journal:  Otolaryngol Head Neck Surg       Date:  2004-12       Impact factor: 3.497

Review 7.  Rhinosinusitis: establishing definitions for clinical research and patient care.

Authors:  Eli O Meltzer; Daniel L Hamilos; James A Hadley; Donald C Lanza; Bradley F Marple; Richard A Nicklas; Claus Bachert; James Baraniuk; Fuad M Baroody; Michael S Benninger; Itzhak Brook; Badrul A Chowdhury; Howard M Druce; Stephen Durham; Berrylin Ferguson; Jack M Gwaltney; Michael Kaliner; David W Kennedy; Valerie Lund; Robert Naclerio; Ruby Pawankar; Jay F Piccirillo; Patricia Rohane; Ronald Simon; Raymond G Slavin; Alkis Togias; Ellen R Wald; S James Zinreich
Journal:  J Allergy Clin Immunol       Date:  2004-12       Impact factor: 10.793

Review 8.  Pathogenesis of nasal polyposis.

Authors:  K E Hulse; W W Stevens; B K Tan; R P Schleimer
Journal:  Clin Exp Allergy       Date:  2015-02       Impact factor: 5.018

9.  Evidence of a role for B cell-activating factor of the TNF family in the pathogenesis of chronic rhinosinusitis with nasal polyps.

Authors:  Atsushi Kato; Anju Peters; Lydia Suh; Roderick Carter; Kathleen E Harris; Rakesh Chandra; David Conley; Leslie C Grammer; Robert Kern; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2008-04-14       Impact factor: 10.793

Review 10.  Mediators in nasal polyposis.

Authors:  Claus Bachert; Philippe Gevaert; Gabriele Holtappels; Paul van Cauwenberge
Journal:  Curr Allergy Asthma Rep       Date:  2002-11       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.